Skip to content
The European patent approval provides protection until 2041. "It ensures strong protection for GmPcides, which is crucial in our industry" states Markus Thor, CEO of QureTech Bio.
The European patent approval provides protection until 2041. "It ensures strong protection for GmPcides, which is crucial in our industry" states Markus Thor, CEO of QureTech Bio.

Press release -

QureTech Bio granted European patent for new class of antibacterials

QureTech Bio AB has been granted a patent by the European Patent Office (EPO) for GmPcides, a new class of synthetic antibacterials.

QureTech’s GmPcides represents an innovative class of small-molecule synthetic antibiotics that effectively target drug-resistant bacteria, including MRSA, with no evidence of resistance development.

The European patent approval, which provides protection until 2041, marks a significant milestone for the Umeå-based biotech company. The patent has already been approved in China and is pending in the USA, India, and Japan.

“We are pleased to receive this patent grant from the European Patent Office,” says Markus Thor, CEO of QureTech Bio.

“The patent ensures strong protection for GmPcides, which is crucial in our industry, and represents a significant step toward making our compounds available to patients in need of effective treatment for drug-resistant bacteria.”

The European Patent Office (EPO) granted the patent application titled “Ring-fused 2-pyridone compounds, methods for their preparation, and their use in the treatment and/or prevention of diseases involving Gram-positive bacteria” on February 26.

Topics

Categories


Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Contacts

Related content

  • Alice Kempe, Chairman of the Board at Kempestiftelserna, and Markus Thor, the CEO of QureTech Bio. Kempestiftelserna is a new shareholder in QureTech Bio, which is developing novel antibiotics and anti-infectives.

    QureTech Bio secures major investment from Kempestiftelserna

    QureTech Bio has secured a SEK 14 million investment from Kempestiftelserna and Nascent Invest to enhance its development of innovative antibiotics targeting antimicrobial resistance. The funding will accelerate programs addressing multidrug-resistant bacteria, significantly impacting global health advancements.